33 employees
KaliVir Immunotherapeutics develops oncolytic viral immunotherapy programs for the treatment of cancer.
2019
KaliVir Immunotherapeutics raised undisclosed on March 16, 2022
Investors: Premier Partners, Company K Partners and QUAD Investment Management